论文部分内容阅读
5型磷酸二酯酶(PDE5)抑制剂起先被研究用于心血管疾病,而后则被研发并获准用于按需治疗勃起功能障碍(ED)。数年以前,西地那非被批准用于治疗肺动脉高压,因此重新引起了研究者对PDE5抑制剂治疗心血管疾病的兴趣。而且他达拉非每日一次的治疗方案也被用于治疗ED。鉴于PDE5在人体内的广泛分布并涉及多种生理功能,PDE5抑制剂未来的发展前景又将是怎样的呢?为了探索这一问题,Konstantinos
Inhibitors of type 5 phosphodiesterase (PDE5) were first studied for cardiovascular disease and then developed and approved for on-demand treatment of erectile dysfunction (ED). Several years ago, sildenafil was approved for the treatment of pulmonary hypertension, thus rerouting researchers’ interest in PDE5 inhibitors for the treatment of cardiovascular disease. And the once-daily treatment of Tadalafil has also been used to treat ED. In view of the widespread distribution of PDE5 in the human body and the involvement of multiple physiological functions, what are the future developmental prospects of PDE5 inhibitors? To explore this issue, Konstantinos